Sirna Therapeutics said this week that it has appointed Rebecca Galler Robinson as the company’s senior director of corporate strategy. In her position, Robinson will be responsible for expanding Sirna’s position in the corporate and investment communities.
She will report to Martin Schmieg, Sirna’s CFO, the company said.
Robinson most recently served as director of private equity in Invesco Funds Group, where she managed a $130 million private equity portfolio comprised of 26 predominately life science and medical device companies, Sirna said. Before this, she was an associate on the healthcare team at GE Equity, the private equity and venture capital division of General Electric.
Robinson has also held positions at the National Institutes of Health, Preferred Global Health, and Interscience. She holds an MBA from Columbia Business School and a BA from Barnard College.
Atugen said this week that Cy Stein has joined the company’s scientific advisory board.
Stein is head of medical genitourinary oncology and professor of medicine, urology, and molecular pharmacology at the Albert Einstein College of Medicine. He is also on the scientific advisory board of Benitec and a scientific advisor to Genta.
Stein has held positions at Columbia University Medical Center and the National Cancer Institute, and has an MD from the Albert Einstein College of Medicine. He has a PhD from Stanford University and a BS from Brown University.
Evotec OAI said last week that Mary Tanner has been elected to the company’s supervisory board.
Tanner has 22 years of senior-level management experience in healthcare and consumer products at Lehman Brothers and Bear Stearns, Evotec said. Tanner retired from Bear Stearns in 2004, and founded Life Sciences Partners, a healthcare investment and advisory firm.
Tanner obtained a degree from Harvard University in 1973 in philosophy and related fields, Evotec said.